🚀 VC round data is live in beta, check it out!
Apotea Valuation Multiples
Discover revenue and EBITDA valuation multiples for Apotea and similar public comparables like Betterware de Mexico, Cachet Pharmaceuticals, Temple & Webster, THG and more.
Apotea Overview
About Apotea
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
Founded
2012
HQ
Employees
831
Website
Financials (LTM)
EV
$678M
Apotea Financials
Apotea reported last 12-month revenue of $813M and EBITDA of $53M.
In the same LTM period, Apotea generated $219M in gross profit, $53M in EBITDA, and $26M in net income.
Revenue (LTM)
Apotea P&L
In the most recent fiscal year, Apotea reported revenue of $801M and EBITDA of $51M.
Apotea expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $813M | XXX | $801M | XXX | XXX | XXX |
| Gross Profit | $219M | XXX | $205M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA | $53M | XXX | $51M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $26M | XXX | $25M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 3% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Apotea Stock Performance
Apotea has current market cap of $646M, and enterprise value of $678M.
Market Cap Evolution
Apotea's stock price is $6.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $678M | $646M | — | XXX | XXX | XXX | $0.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialApotea Valuation Multiples
Apotea trades at 0.8x EV/Revenue multiple, and 12.7x EV/EBITDA.
EV / Revenue (LTM)
Apotea Financial Valuation Multiples
As of March 28, 2026, Apotea has market cap of $646M and EV of $678M.
Equity research analysts estimate Apotea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Apotea has a P/E ratio of 25.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $646M | XXX | $646M | XXX | XXX | XXX |
| EV (current) | $678M | XXX | $678M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 12.7x | XXX | 13.2x | XXX | XXX | XXX |
| EV/EBIT | 19.8x | XXX | 20.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | 3.3x | XXX | XXX | XXX |
| P/E | 25.1x | XXX | 25.7x | XXX | XXX | XXX |
| EV/FCF | 37.7x | XXX | 53.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Apotea Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Apotea Margins & Growth Rates
Apotea's revenue in the last 12 month grew by 8%.
Apotea's revenue per employee in the last FY averaged $1.0M.
Apotea's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Apotea's rule of X is 27% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Apotea Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Apotea Public Comps
See public comps and valuation multiples for other Pharmacies and Consumer E-commerce comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Betterware de Mexico | XXX | XXX | XXX | XXX | XXX | XXX |
| Cachet Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Temple & Webster | XXX | XXX | XXX | XXX | XXX | XXX |
| THG | XXX | XXX | XXX | XXX | XXX | XXX |
| Lily & Beauty | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apotea M&A Activity
Apotea acquired XXX companies to date.
Last acquisition by Apotea was on XXXXXXXX, XXXXX. Apotea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Apotea
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialApotea Investment Activity
Apotea invested in XXX companies to date.
Apotea made its latest investment on XXXXXXXX, XXXXX. Apotea invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Apotea
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Apotea
| When was Apotea founded? | Apotea was founded in 2012. |
| Where is Apotea headquartered? | Apotea is headquartered in Sweden. |
| How many employees does Apotea have? | As of today, Apotea has over 831 employees. |
| Is Apotea publicly listed? | Yes, Apotea is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Apotea? | Apotea trades under APOTEA ticker. |
| When did Apotea go public? | Apotea went public in 2024. |
| Who are competitors of Apotea? | Apotea main competitors are Betterware de Mexico, Cachet Pharmaceuticals, Temple & Webster, THG. |
| What is the current market cap of Apotea? | Apotea's current market cap is $646M. |
| What is the current revenue of Apotea? | Apotea's last 12 months revenue is $813M. |
| What is the current revenue growth of Apotea? | Apotea revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Apotea? | Current revenue multiple of Apotea is 0.8x. |
| Is Apotea profitable? | Yes, Apotea is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Apotea? | Apotea's last 12 months EBITDA is $53M. |
| What is Apotea's EBITDA margin? | Apotea's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Apotea? | Current EBITDA multiple of Apotea is 12.7x. |
| What is the current FCF of Apotea? | Apotea's last 12 months FCF is $18M. |
| What is Apotea's FCF margin? | Apotea's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Apotea? | Current FCF multiple of Apotea is 37.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.